Opko Health, Inc. (NASDAQ:OPK)’s share price was up 5.2% during trading on Thursday . The company traded as high as $5.25 and last traded at $5.25. Approximately 4,652,926 shares were traded during mid-day trading, an increase of 2% from the average daily volume of 4,549,510 shares. The stock had previously closed at $4.99.

A number of equities analysts recently commented on OPK shares. Ladenburg Thalmann Financial Services reiterated a “buy” rating and issued a $16.00 target price on shares of Opko Health in a research report on Monday, September 25th. Cantor Fitzgerald set a $20.00 target price on shares of Opko Health and gave the stock a “buy” rating in a research report on Wednesday, October 25th. Zacks Investment Research upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research report on Thursday, October 26th. Jefferies Group reiterated a “hold” rating and issued a $6.50 target price (down previously from $6.80) on shares of Opko Health in a research report on Thursday, August 10th. Finally, BidaskClub upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research report on Saturday, September 23rd. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $13.97.

The company has a quick ratio of 1.48, a current ratio of 1.66 and a debt-to-equity ratio of 0.01.

Opko Health (NASDAQ:OPK) last released its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03). Opko Health had a negative net margin of 9.45% and a negative return on equity of 5.17%. The firm had revenue of $263.50 million during the quarter, compared to analysts’ expectations of $319.43 million. During the same quarter in the previous year, the firm posted ($0.03) EPS. Opko Health’s revenue was down 11.6% compared to the same quarter last year. equities analysts anticipate that Opko Health, Inc. will post -0.27 earnings per share for the current year.

In related news, CEO Phillip Md Et Al Frost bought 80,000 shares of the business’s stock in a transaction dated Friday, September 15th. The shares were purchased at an average price of $6.01 per share, with a total value of $480,800.00. Following the purchase, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at approximately $18,444,395.51. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Opko Health, Inc. bought 655,738 shares of the business’s stock in a transaction dated Monday, October 30th. The shares were bought at an average cost of $3.05 per share, for a total transaction of $2,000,000.90. Following the purchase, the insider now directly owns 6,678,752 shares in the company, valued at approximately $20,370,193.60. The disclosure for this purchase can be found here. Insiders acquired 1,052,238 shares of company stock worth $4,374,796 in the last 90 days. Corporate insiders own 40.19% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. Blair William & Co. IL bought a new stake in shares of Opko Health during the 2nd quarter valued at about $112,000. Engineers Gate Manager LP bought a new stake in Opko Health during the second quarter worth about $117,000. Crossmark Global Holdings Inc. bought a new stake in Opko Health during the third quarter worth about $118,000. IFC Holdings Incorporated FL boosted its stake in Opko Health by 16.5% during the second quarter. IFC Holdings Incorporated FL now owns 17,864 shares of the biotechnology company’s stock worth $119,000 after acquiring an additional 2,525 shares in the last quarter. Finally, Abbot Financial Management Inc. bought a new stake in Opko Health during the second quarter worth about $129,000. 22.92% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Opko Health (OPK) Trading Up 5.2%” was first reported by Daily Political and is owned by of Daily Political. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://www.dailypolitical.com/2017/11/30/opko-health-opk-trading-up-5-2.html.

Opko Health Company Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.